Symphogen, a Denmark-based developer of antibody therapeutics to treat cancer and disease, has added €41m ($54m) to its previous round.

Novo, a $20bn quasi-corporate venturing investment company wholly owned by the Novo Nordisk Foundation, and local pension fund PKA each invested €20m, with Danica Pension co-investing.

Henrik Gürtler, chief executive of Novo, said: “It is important to understand the significance of the investments of Danica Pension and PKA.

“This is Danica Pension’s first active investment in Symphogen, where they are…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?